読み込み中
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
通常取引
$23.36
−$0.32 · -1.35%
日中の時刻はETです。市場データは遅延する場合があります。
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
日中レンジ
現在 $23.36
52週レンジ
現在 $23.36
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
45
適正価値
センチメント
49
まちまち
リスク
54
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
日中レンジ
現在 $23.36
52週レンジ
現在 $23.36
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2964.3万 EUR | −719万 EUR | 3620.8万 EUR | 477.6万 EUR | 264.7万 EUR |
| 粗利益 | 2964.3万 EUR | −719万 EUR | 3620.8万 EUR | 477.6万 EUR | 264.7万 EUR |
| 研究開発 | 2311.5万 EUR | 4054.1万 EUR | 3839.6万 EUR | 3263.6万 EUR | 3037.8万 EUR |
| 販売・一般管理 | 2022.2万 EUR | 2052.7万 EUR | 2204.9万 EUR | 1785.7万 EUR | 1943.4万 EUR |
| 営業費用 | 4046.1万 EUR | 6120.2万 EUR | 6298.7万 EUR | 5147.8万 EUR | 5522.6万 EUR |
| 受取利息 | 98.5万 EUR | 262.9万 EUR | 121.7万 EUR | 25.6万 EUR | — |
| 支払利息 | 1039.5万 EUR | 808.6万 EUR | 798.2万 EUR | 583.7万 EUR | 69.95万 EUR |
| 減価償却費と償却費 | 149.5万 EUR | 162.1万 EUR | 151.3万 EUR | 150万 EUR | 156万 EUR |
| 営業利益 | −1081.8万 EUR | −6839.2万 EUR | −2677.9万 EUR | −4670.2万 EUR | −5257.9万 EUR |
| 純利益 | −2396.1万 EUR | −6813.2万 EUR | −3970万 EUR | −5704.1万 EUR | −4700.3万 EUR |
会社概要が更新されました 2026年10月12日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$38.00
上昇余地（62.67%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
